Summary of Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings

June 27, 2018 - By Alex Paulin

Seattle Genetics, Inc. (NASDAQ:SGEN) Corporate Logo
Big Money Sentiment increased to 1.61 in 2018 Q1. It has change of 0.38, from 2017Q4’s 1.23. The ratio is positive due to Seattle Genetics, Inc. positioning: 24 sold and 53 reduced. 31 funds bought stakes and 93 increased stakes. Investors holded 141.83 million in 2017Q4 but now own 159.52 million shares or 12.47% more.
Barclays Public Ltd Co holds 0% or 33,675 shs in its capital. Schwab Charles Mgmt has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Perkins Coie reported 0% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN). Profund Advsrs Ltd accumulated 0.07% or 35,115 shs. 29,932 were reported by Tudor Et Al. Eaton Vance Mngmt accumulated 5,000 shs. Huntington Savings Bank owns 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 500 shs. Moreover, Piedmont Ltd Liability has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 9,366 shs. South Dakota Invest Council, a South Dakota-based fund reported 42,200 shs. Opus Point Partners Mgmt Limited Company reported 2.17% in Seattle Genetics, Inc. (NASDAQ:SGEN). Parametric Associates Lc reported 106,975 shs. Fjarde Ap invested in 34,540 shs or 0.03% of the stock. Vantage Inv Advsrs Limited Liability Corporation has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Brown Advisory holds 0.01% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN) for 29,145 shs. Shell Asset Management Comm holds 0.01% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN) for 4,998 shs.

Seattle Genetics, Inc. had 12 insider sales and 3 insider purchases since January 11, 2018. This’s net activity of $266.95 million. 12,054 Seattle Genetics, Inc. (NASDAQ:SGEN) shs with value of $831,688 were sold by Cline Darren S. $290,604 worth of stock was sold by HIMES VAUGHN B on Thursday, March 15. 10,457 shs valued at $552,452 were sold by DRACHMAN JONATHAN G on Monday, March 5. On Monday, April 30 the insider BAKER BROS. ADVISORS LP bought $51.26M.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

In total 8 analysts cover Seattle Genetics (NASDAQ:SGEN). “Buy” rating has 7, “Sell” are 0, while 1 are “Hold”. 88% are bullish. 12 are the (NASDAQ:SGEN)’s analyst reports since January 31, 2018 according to StockzIntelligence Inc. The company rating was maintained by RBC Capital Markets on Tuesday, March 20. On Wednesday, February 7 the rating was maintained by H.C. Wainwright with “Buy”. On Wednesday, February 14 the firm has “Overweight” rating by JP Morgan given. On Wednesday, February 7 the firm has “Hold” rating by SunTrust given. On Wednesday, February 7 the stock has “Neutral” rating by Bank of America. On Wednesday, March 21 the rating was maintained by Morgan Stanley with “Overweight”. On Wednesday, February 7 Needham maintained the shares of SGEN in report with “Buy” rating. On Monday, June 11 the stock has “Buy” rating by SunTrust. On Thursday, February 1 the stock has “Buy” rating by H.C. Wainwright. On Wednesday, February 14 the stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Buy” rating given by J.P. Morgan. Listed here are Seattle Genetics, Inc. (NASDAQ:SGEN) PTs and latest ratings.

11/06/2018 Broker: SunTrust Rating: Buy Upgrade
27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0000 Maintain
21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $67 Maintain
20/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $73.0 Maintain
14/02/2018 Broker: J.P. Morgan Rating: Buy New Target: $66.0 Upgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $60 Upgrade
07/02/2018 Broker: Needham Rating: Buy New Target: $74.0 Maintain
07/02/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $70 New Target: $68 Maintain
07/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0 Maintain
07/02/2018 Broker: SunTrust Rating: Hold New Target: $60.0 Maintain

Ticker’s shares touched $65.39 during the last trading session after 0.43% change.Seattle Genetics, Inc. has volume of 296,186 shares. Since June 27, 2017 SGEN has declined 15.50% and is downtrending. SGEN underperformed the S&P500 by 28.07%.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide.The firm is valued at $10.35 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.Last it reported negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

A couple more Seattle Genetics, Inc. (NASDAQ:SGEN) news were posted by: Seekingalpha.com which released on June 13, 2018 “Immunomedics: Short-Term Risk, Long-Term Opportunity”, also Nasdaq.com on June 26, 2018 posted “Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta …”, the next Seekingalpha.com is “Premarket analyst action – healthcare” on June 11, 2018. Streetinsider.com has article titled “SunTrust Robinson Humphrey Upgrades Seattle Genetics (SGEN) to Buy; Improving Prospects For Adcetris In 1L HL”.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.